NEW YORK, July 10 - ActivX Biosciences has raised $20 million in a private placement to develop the company's chemistry-based proteomics platform, the company said Tuesday. 

In addition to Oxford Bioscience Partners, who led the placement, new investors in the company include Vulcan Ventures, CIT Venture Capital, and Novo A/S. Frazier & Company and ProQuest Investments are existing investors in the company.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.